Giorgio Trinchieri, M.D.
Director of the Cancer and Inflammation Program and Chief of the Laboratory of Experimental Immunology, NCI
Giorgio Trinchieri, M.D., is the Director of the Cancer and Inflammation Program and Chief of the Laboratory of Experimental Immunology, Center for Cancer Research, NCI, Frederick, MD. Dr. Trinchieri received a medical degree from the University of Torino, Italy, in 1973. He was a member of the Basel Institute for Immunology (Basel, Switzerland) and an investigator at the Swiss Institute for Experimental Cancer Research (Epalanges sur Lausanne, Switzerland). From 1979 to 1999 he was at Wistar Institute in Philadelphia and became Hilary Koprowski Professor and Chairman of the Immunology Program; he was also Wistar Professor of Medicine at the University of Pennsylvania. He has been interested for many years in the interplay between inflammation/innate resistance and adaptive immunity, and in the role of pro-inflammatory cytokines and interferons in the regulation of haematopoiesis, innate resistance and immunity.
In 1989, his group at the Wistar Institute discovered Interleukin-12, and he has spent many years characterizing the molecular mechanisms of IL-12 production and action, and the role of this molecule in tumour immunity, infections and autoimmunity. He became the director of the Schering Plough Laboratory for Immunological Research in Dardilly, France, from 1999 to 2004 where he established a program of biology and drug discovery for targeting innate immunity and establishing protocols of cancer immunotherapy. He returned to the States as a NIH Fogarty Scholar at the Laboratory for Parasitic Diseases, NIAID, before becoming director of the Cancer and Inflammation Program (CIP) and chief of the Laboratory of Experimental Immunology at NCI in August 2006. As CIP director, he oversees the operations of two major NCI intramural laboratories, the Laboratory of Experimental Immunology and the Laboratory of Molecular Immunoregulation. These two laboratories constitute the major immunologic component of the CCR’s inflammation and cancer initiative, which spans the NCI’s campuses in Frederick and Bethesda and seeks to partner NCI’s expertise in inflammation and immunology with its cutting-edge cancer etiology and carcinogenesis program.
His main focus of research is presently the role of inflammation, innate resistance, and immunity in carcinogenesis, cancer progression, and prevention or destruction of cancer. Dr. Trinchieri has published over 250 research papers and over 150 reviews or book chapters. He is co-inventor on 21 patents covering the discovery and use of cytokines and antibodies in therapy of cancer, autoimmunity, and infectious diseases. He is in the editorial board of 7 scientific journals and Deputy Editor of Cancer Research. He is a founding member of the Academy of Cancer Immunology, a fellow of the American Academy of Microbiology and an honorary member of the Italian Society of Immunology and Allergy. He is the recipient of the Cancer Research Institute’s W. B. Coley Award for Distinguished Research in Basic and Clinical Immunology and of the International Society for Interferon and Cytokine Research’ Milstein Award for outstanding research in the field of Interferon and Cytokines.
Last Updated July 2010